Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2024-04-25 Regulatory Filings
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
zal05_SzDZ2023_2024-04-24_pl.xhtml.xades
Regulatory Filings Classification · 1% confidence The provided document text consists entirely of XML digital signature blocks (specifically XAdES signatures, indicated by namespaces like 'ds' and 'xades'). These signatures contain metadata about the signing process, certificates, and references to the actual content (URI="SzDZ2023_2024-04-24_pl.xhtml"). The text itself does not contain any financial data, management discussion, or regulatory narrative. This structure strongly suggests the document is either a digitally signed file wrapper or a document where the primary content is the signature itself, which is common for regulatory filings that require authentication. Since the content is not the report (like 10-K or IR) but rather the mechanism securing the report, and given the presence of multiple signatures and the nature of the content being purely technical/metadata, it is most likely a component of a larger regulatory submission or a miscellaneous filing. Given the options, and the fact that this is a technical artifact rather than a narrative report, 'Regulatory Filings' (RNS) is the most appropriate fallback category for an unclassifiable technical component of a filing, although it could also be interpreted as an attachment/supplement (XLSX) if the referenced file was the main document. However, classifying the signature block itself points towards a general regulatory artifact.
2024-04-25 Polish
Sprawozdanie z działalności Zarządu Celon Pharma S.A. w 2023
Board/Management Information Classification · 1% confidence The document text provided is an HTML structure generated by a tool called 'pdf2htmlEX' from a source file named 'SzDZ2023_2024-04-24_pl.xhtml'. The content itself is primarily CSS styling and structural elements for rendering a PDF, not the actual financial report content. However, the filename 'SzDZ2023_2024-04-24_pl.xhtml' suggests a document related to a specific date (April 24, 2024) and potentially a Polish regulatory filing ('pl'). Given the context of financial documents, and the lack of specific content keywords (like '10-K', 'Earnings Release', 'Proxy'), this is most likely a general regulatory filing or an attachment that doesn't fit a specific category. Since the document is clearly a rendered file (not a short announcement) but its content is inaccessible/unreadable in this format, and it doesn't match any specific report type, the most appropriate fallback is 'Regulatory Filings' (RNS), as it represents a general filing that doesn't fit the defined categories based on the provided text structure.
2024-04-25 Polish
zal01_SF2023_12M_2024-04-24_pl.xhtml.xades
Regulatory Filings Classification · 1% confidence The provided document text consists entirely of XML digital signature blocks ('Signature', 'SignedInfo', 'KeyInfo', 'X509Certificate', etc.). This structure is characteristic of a digitally signed file, often an attachment or the document itself being validated. The reference URI within the signature block points to 'SF2023_12M_2024-04-24_pl.xhtml', which suggests a financial statement or report for the 12 months ending in 2023, signed on April 24, 2024. Since the document provided is only the signature metadata and not the content of the report (which is referenced as an external file), and given the document length is relatively short (25,033 chars, which is small for a full 10-K or IR), this strongly suggests the document is an announcement *about* a filing or a regulatory filing wrapper, rather than the comprehensive report itself. The presence of multiple signatures (two distinct 'Signature' blocks) and the nature of the content (pure XML signature structure) points towards a general regulatory filing or an announcement wrapper. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a document that is essentially a digitally signed container or metadata wrapper that doesn't fit the specific report types (like 10-K, IR, ER). If the referenced file 'SF2023_12M_2024-04-24_pl.xhtml' were present, it might be classified as 'IR' (Interim/Quarterly Report) or '10-K' (Annual Report), but as presented, it is just the signature data.
2024-04-25 Polish
Sprawozdanie finansowe Spółki Celon Pharma S.A.
Audit Report / Information Classification · 1% confidence The document text provided is extremely long (over 3.8 million characters) and appears to be the raw HTML/CSS structure generated from converting a PDF document, as indicated by the presence of extensive CSS styling, font definitions (woff data), and the title 'SF2023_12M_2024-04-24_pl.xhtml'. The content itself is not the narrative or structured data of a financial report but rather the rendering instructions for that report. Given the length and the nature of the content (a full document conversion artifact), it is highly likely that the original source document was a comprehensive financial filing, such as an Annual Report (10-K) or an Interim Report (IR). However, since the provided text is the *container* or *rendering* of the document rather than the document's actual content (like tables, MD&A, or specific disclosures), and it is not a short announcement pointing to a report, the most appropriate classification for a full, comprehensive report that has been converted to this format is the Annual Report (10-K) or Interim Report (IR). The title 'SF2023_12M' suggests a 12-Month (12M) filing for the year 2023, which strongly points towards an Annual Report (10-K) or a comprehensive annual filing. Since the document is massive and represents the full content, 10-K is the best fit for a full annual filing. FY 2023
2024-04-25 Polish
Przekazanie informacji o wprowadzeniu produktu leczniczego ZARIXA do regulatorów rynku farmaceutycznego - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is very short (975 characters) and discusses regulatory actions concerning the introduction of a pharmaceutical product (ZARIXA) into circulation in Poland, referencing previous reports and interactions with regulatory bodies (Prezes Urzędu Rejestracji Produktów Leczniczych, Główny Inspektor Farmaceutyczny). This content relates to product approval, regulatory compliance, and market entry for a specific drug. It is not a comprehensive financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it details specific regulatory compliance steps and product market entry following a prior decision, it fits best under the general category for regulatory announcements that don't fit other specific financial or corporate governance codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific, non-financial regulatory update of this nature, as it is a formal communication to the market about compliance steps.
2024-04-18 Polish
Powołanie Prezesa Zarządu Spółki na kolejną kadencję - Content (PL)
Board/Management Information Classification · 1% confidence The document text is a formal announcement from the Management Board ('Zarząd') of Celon Pharma S.A. regarding the reappointment of Mr. Maciej Wieczorek as the President of the Management Board ('Prezesa Zarządu') for a new five-year term, effective after the AGM approves the 2023 financial statements. This announcement details the individual's qualifications, education, professional history, and compliance statements. This content directly relates to changes or appointments within the senior management/board structure of the company. Therefore, it fits the definition of Board/Management Information (MANG). The document length (2931 chars) is substantial enough to be the primary announcement, not just a brief notice of publication.
2024-01-24 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.